POPULATION PHARMACOKINETICS OF LEVODOPA AND CARBIDOPA FOLLOWING SUBCUTANEOUS INFUSION

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Smania, G. [2 ]
Bjornsson, M. [2 ]
Jonsson, N. [2 ]
Case, R. [2 ]
Karlsson, M. O. [3 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Pharmetheus, Uppsala, Sweden
[3] Uppsala Univ, Uppsala, Sweden
来源：
PARKINSONISM & RELATED DISORDERS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P 121
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [31] Measuring Motor Improvement with a Wearable Device in a Parkinson Disease Patient undergoing Subcutaneous Levodopa Carbidopa Infusion
    Lopez Ariztegui, N.
    Morales Casado, M. I.
    Tabar Comellas, G.
    MOVEMENT DISORDERS, 2024, 39 : S585 - S585
  • [32] Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients
    Senek, Marina
    Nyholm, Dag
    Nielsen, Elisabet I.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (10) : 1299 - 1307
  • [33] Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
    Marina Senek
    Dag Nyholm
    Elisabet I. Nielsen
    European Journal of Clinical Pharmacology, 2018, 74 : 1299 - 1307
  • [34] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, L.
    Vostokova, N.
    MOVEMENT DISORDERS, 2022, 37 : S438 - S439
  • [35] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, Liat
    Vostokova, Natalia
    NEUROLOGY, 2023, 100 (17)
  • [36] Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
    Birnberg, T.
    Smania, G.
    Bjornsson, M.
    Jonsson, N.
    Case, R.
    Oren, S.
    Adar, L.
    Karlsson, M.
    MOVEMENT DISORDERS, 2020, 35 : S389 - S389
  • [37] The pharmacokinetics of patients with Parkinson's disease receiving levodopa-carbidopa intestinal gel infusion therapy
    Mukai, Y.
    Miyazaki, M.
    Mukai, T.
    Tasaki, A.
    Yuji, T.
    Murata, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 586 - 586
  • [38] Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel
    Taher, Jennifer
    Naranian, Taline
    Poon, Yu-Yan
    Merola, Aristide
    Mestre, Tiago
    Suchowersky, Oksana
    Kulasingam, Vathany
    Fasano, Alfonso
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (01) : 19 - 28
  • [39] Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
    Ahmed A. Othman
    Krai Chatamra
    Mohamed-Eslam F. Mohamed
    Sandeep Dutta
    Janet Benesh
    Masayoshi Yanagawa
    Masahiro Nagai
    Clinical Pharmacokinetics, 2015, 54 : 975 - 984
  • [40] Enrolment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612
    Rascol, O.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J.
    Gurevich, T.
    Hassin, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Manzanares, L. Lopez
    Olanow, C.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Salin, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Espay, A.
    Giladi, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 708 - 709
12345